Recently, Salubris announced that NMPA has accepted the marketing application of its self-developed SAL0107.
SAL0107 is an ARB/CCB compound preparation for treating patients with primary hypertension with poor blood pressure control after Allisartan or Amlodipine mono-therapy.
After the launch of the product, it will form a strategic synergy with Xinlitan (Allisartan Isoproxil tablets), a class 1.1 antihypertensive marketed drug, further enrich the innovative product pipeline in cardiovascular area, cover a broader population of hypertensive patients, provide patients with more medication options, and enhance the comprehensive competitiveness of Salubris in the field of chronic disease.
Drug name: SAL0107
Application information: Registration and marketing authorization for domestically produced drugs
Registry Classification: 2.3 category
Drug Type: Chemical
Acceptance number: CXHS2200061
Acceptance instructions: According to the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, it is decided to accept it after examination.